GenEmbryomics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Latest Deal Amount
  • $10.3M

  • Investors
  • 4

GenEmbryomics General Information

Description

GenEmbryomics Ltd is a genomics-based company empowering families to have healthy children by providing in-vitro fertilization (IVF) patients and providers insights into an embryo's genetic disease. Its test Panacea-GenomeScreen provides preimplantation genetic testing via whole genome sequencing (PGT-WGS) of individuals, couples and IVF embryos..

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 580 California Street
  • 12th Floor 9971
  • San Francisco, CA 94104
  • United States
+1 (888)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 580 California Street
  • 12th Floor 9971
  • San Francisco, CA 94104
  • United States
+1 (888)

GenEmbryomics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GenEmbryomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. IPO 23-Apr-2025 $10.3M Cancelled Generating Revenue
3. Accelerator/Incubator 25-Jul-2024 Completed Generating Revenue
2. Debt - General 01-Aug-2023 Completed Generating Revenue
1. Early Stage VC 14-Jun-2022 Completed Generating Revenue
To view GenEmbryomics’s complete valuation and funding history, request access »

GenEmbryomics Patents

GenEmbryomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020369151-A1 Method for screening ivf embryos Pending 22-Oct-2019
EP-4048810-A1 Method for screening ivf embryos Pending 22-Oct-2019
EP-4048810-A4 Method for screening ivf embryos Pending 22-Oct-2019
US-20220392570-A1 Method for screening ivf embryos Pending 22-Oct-2019
WO-2021077163-A1 Method for screening ivf embryos Inactive 22-Oct-2019 G16B20/20
To view GenEmbryomics’s complete patent history, request access »

GenEmbryomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GenEmbryomics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Medtech Actuator Accelerator/Incubator Minority
Artesian Venture Capital Minority
Boab Venture Capital Minority
Homu Health Ventures Venture Capital Minority
To view GenEmbryomics’s complete investors history, request access »

GenEmbryomics FAQs

  • When was GenEmbryomics founded?

    GenEmbryomics was founded in 2019.

  • Where is GenEmbryomics headquartered?

    GenEmbryomics is headquartered in San Francisco, CA.

  • What is the size of GenEmbryomics?

    GenEmbryomics has 5 total employees.

  • What industry is GenEmbryomics in?

    GenEmbryomics’s primary industry is Biotechnology.

  • Is GenEmbryomics a private or public company?

    GenEmbryomics is a Private company.

  • What is the current valuation of GenEmbryomics?

    The current valuation of GenEmbryomics is .

  • What is GenEmbryomics’s current revenue?

    The current revenue for GenEmbryomics is .

  • How much funding has GenEmbryomics raised over time?

    GenEmbryomics has raised $860K.

  • Who are GenEmbryomics’s investors?

    Medtech Actuator, Artesian, Boab, and Homu Health Ventures have invested in GenEmbryomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process